INS and type 2 diabetes mellitus: In an early RCT examining CGM use by Garg et al., 91 insulin-requiring patients with diabetes (75 with T1D and 16 with T2D) were randomized to receive 3 days of rtCGM (STS, Dexcom) or masked CGM (control).33 When compared with control subjects, the CGM group spent 21% less time in hypoglycemia (<55 mg/dL), 23% less time in hyperglycemia (≥240 mg/dL), and 26% more time in the target (81–140 mg/dL) glucose range.